Todays Report: Today, Becton Dickinson and Co. (BDX) Upgrade to Buy by The Zacks Investment Research

Today, Becton Dickinson and Co. (BDX) Upgrade to Buy by The Zacks Investment Research

Becton Dickinson and Co. (NYSE:BDX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday. The firm currently has a $189.00 price target on the stock. Zacks Investment Research’s target price suggests a potential upside of 12.18% from the company’s previous close.

According to Zacks, “Becton, Dickinson and Company, popularly known as BD, reported an impressive fourth quarter of fiscal 2016, beating the Zacks Consensus Estimate on both counts. The recent collaboration of BD with JDRF, the leading global organization funding type 1 diabetes research is a significant positive in our view. Additionally, the launch of the BD U-500 Insulin Syringe fortifies the company’s position in the niche market of insulin infusion technologies. BD has been gaining prominence in the market with the partnership with Vyaire Medical, the launch of BD Phoenix M50 ID/AST system and further investments to expand the capacity for its insulin syringe manufacturing operation. The company’s new launches FACSymphony, FACSCelesta and FACSMelody has also gained significant traction within a short span of time.”

Several other analysts have also commented on the stock. Leerink Swann reiterated a “market perform” rating and issued a $185.00 price target (up from $180.00) on shares of Becton Dickinson and in a research report on Monday. Deutsche Bank AG restated a “buy” rating and set a $189.00 target price (down previously from $197.00) on shares of Becton Dickinson and in a research report on Friday, November 4th. Argus restated a “buy” rating and set a $185.00 target price on shares of Becton Dickinson and in a research report on Friday, October 21st. Citigroup Inc. lowered shares of Becton Dickinson and from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $167.00 to $165.00 in a research report on Friday, September 23rd. Finally, Cowen and Company restated an “outperform” rating and set a $185.00 target price on shares of Becton Dickinson and in a research report on Tuesday, August 16th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $175.65.

Shares of Becton Dickinson and (NYSE:BDX) opened at 168.48 on Friday. The stock’s 50 day moving average price is $171.92 and its 200-day moving average price is $172.32. The stock has a market cap of $35.87 billion, a price-to-earnings ratio of 37.52 and a beta of 1.04. Becton Dickinson and has a 52-week low of $129.50 and a 52-week high of $181.76.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 3rd. The company reported $2.12 EPS for the quarter, beating the consensus estimate of $2.09 by $0.03. The business had revenue of $3.23 billion for the quarter, compared to analyst estimates of $3.22 billion. Becton Dickinson and had a net margin of 7.82% and a return on equity of 24.44%. The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.94 earnings per share. On average, analysts predict that Becton Dickinson and will post $9.52 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 30th. Stockholders of record on Friday, December 9th will be paid a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.73%. The ex-dividend date is Wednesday, December 7th. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.66. Becton Dickinson and’s dividend payout ratio (DPR) is currently 58.54%.

In related news, insider Linda M. Tharby sold 11,704 shares of Becton Dickinson and stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $177.27, for a total transaction of $2,074,768.08. Following the sale, the insider now owns 22,146 shares of the company’s stock, valued at approximately $3,925,821.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stephen Sichak sold 10,352 shares of Becton Dickinson and stock in a transaction on Friday, November 4th. The stock was sold at an average price of $176.10, for a total transaction of $1,822,987.20. Following the sale, the insider now directly owns 26,892 shares in the company, valued at approximately $4,735,681.20. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the company. Bollard Group LLC increased its stake in Becton Dickinson and by 0.4% in the second quarter. Bollard Group LLC now owns 1,355 shares of the company’s stock valued at $230,000 after buying an additional 5 shares during the period. Parkside Financial Bank & Trust increased its stake in Becton Dickinson and by 0.8% in the third quarter. Parkside Financial Bank & Trust now owns 624 shares of the company’s stock valued at $113,000 after buying an additional 5 shares during the period. Wellington Shields & Co. LLC increased its stake in Becton Dickinson and by 0.3% in the third quarter. Wellington Shields & Co. LLC now owns 2,517 shares of the company’s stock valued at $452,000 after buying an additional 8 shares during the period. Coldstream Capital Management Inc. increased its stake in Becton Dickinson and by 0.6% in the second quarter. Coldstream Capital Management Inc. now owns 1,495 shares of the company’s stock valued at $254,000 after buying an additional 9 shares during the period. Finally, Northstar Group Inc. increased its stake in Becton Dickinson and by 0.3% in the second quarter. Northstar Group Inc. now owns 2,956 shares of the company’s stock valued at $501,000 after buying an additional 10 shares during the period. 82.68% of the stock is currently owned by hedge funds and other institutional investors.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

Related posts

Leave a Comment